Therefore, the results from the present study indicate that PODXL could be used as a predictive marker for adjuvant treatment of periampullary cancer with intestinal morphology, and possibly also ampullary PB-type tumours. The gene discussed is PODXL; the disease is periampullary adenocarcinoma.